Avacta Group, a biotechnology company dealing in diagnostics and cancer therapies, has entered into a non-exclusive distribution agreement with Calibre Scientific, a global provider of life science products, to distribute and sell Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test in the UK and European Economic Area (EEA). The test will be available on Calibre’s website and can be purchased by professional users only.

Bio-Rad Laboratories has announced the launch of its PREvalence ddPCR SARS-CoV-2 wastewater quantification kit, an accurate, sensitive and cost-effective tool for the detection of the SARS-CoV-2 infection in community wastewater. The assay helps a community to determine if the virus has been present days to weeks ahead before it is detected among individuals.

GenScript Biotech Corporation and Duke-NUS Medical School have announced that a notice of allowance for the patent application for a novel Surrogate Virus Neutralisation Technology (sVNT) has been issued by the US Patent and Trade Office. Neutralising antibodies have been scientifically proven to prevent the SARS-CoV-2 infection by blocking the virus from infecting human cells, and the test can be used to assess immunity to multiple coronaviruses including SARS-CoV-2.